Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Predictors of deviation in neurovascular bundle preservation during robotic prostatectomy.

Couture F, Polesello S, Tholomier C, Bondarenko HD, Karakiewicz PI, Nazzani S, Preisser F, El-Hakim A, Zorn KC.

Can J Urol. 2019 Feb;26(1):9644-9653.

2.

Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.

Kwiatkowska A, Couture F, Ait-Mohand S, Desjardins R, Dory YL, Guérin B, Day R.

Sci Rep. 2019 Feb 14;9(1):2118. doi: 10.1038/s41598-018-37568-6.

3.

Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue.

Dianati V, Navals P, Couture F, Desjardins R, Dame A, Kwiatkowska A, Day R, Dory YL.

J Med Chem. 2018 Dec 1. doi: 10.1021/acs.jmedchem.8b01381. [Epub ahead of print]

PMID:
30501188
4.

Evaluation of PACE4 isoforms as biomarkers in thyroid cancer.

Fradet L, Temmar R, Couture F, Belzile M, Fortier PH, Day R.

J Otolaryngol Head Neck Surg. 2018 Oct 19;47(1):63. doi: 10.1186/s40463-018-0311-x.

5.

Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.

Dianati V, Kwiatkowska A, Couture F, Desjardins R, Dory YL, Day R.

J Med Chem. 2018 Sep 27;61(18):8457-8467. doi: 10.1021/acs.jmedchem.8b01144. Epub 2018 Sep 17.

PMID:
30180568
6.

Isolated peritoneal carcinomatosis from metastatic castration-resistant prostate cancer and associated biliary obstruction: A case report.

Couture F, Chin J, Chong J, Tanguay S.

Urol Case Rep. 2018 Aug 12;21:10-11. doi: 10.1016/j.eucr.2018.08.007. eCollection 2018 Nov. No abstract available.

7.

Use of the AccuVein AV400 during RARP: an infrared augmented reality device to help reduce abdominal wall hematoma.

Law KW, Ajib K, Couture F, Tholomier C, Bondarenko HD, Preisser F, Karakiewicz PI, Zorn KC.

Can J Urol. 2018 Aug;25(4):9384-9388.

8.

Real-world patient- and caregiver-reported outcomes in advanced breast cancer.

Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Tran T, Mates M, Lemieux J, Chabot P, Prady C, Couture F, Lachaine J.

Curr Oncol. 2018 Aug;25(4):e282-e290. doi: 10.3747/co.25.3765. Epub 2018 Aug 14.

9.

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.

De Mattia E, Cecchin E, Montico M, Labriet A, Guillemette C, Dreussi E, Roncato R, Bignucolo A, Buonadonna A, D'Andrea M, Coppola L, Lonardi S, Lévesque E, Jonker D, Couture F, Toffoli G.

Front Pharmacol. 2018 Apr 13;9:367. doi: 10.3389/fphar.2018.00367. eCollection 2018.

10.

Prostate cancer biochemical recurrence after salvage radiotherapy: first look into risk stratification and prognosis.

Couture F, Tholomier C, Zorn KC.

BJU Int. 2018 Mar;121(3):320-321. doi: 10.1111/bju.13978. No abstract available.

11.

NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy.

Roussy M, Bilodeau M, Jouan L, Tibout P, Laramée L, Lemyre E, Léveillé F, Tihy F, Cardin S, Sauvageau C, Couture F, Louis I, Choblet A, Patey N, Gendron P, Duval M, Teira P, Hébert J, Wilhelm BT, Choi JK, Gruber TA, Bittencourt H, Cellot S.

Genes Chromosomes Cancer. 2018 Jun;57(6):311-319. doi: 10.1002/gcc.22532. Epub 2018 Mar 28.

PMID:
29427526
12.

Assessment of urology postgraduate trainees' competencies in flexible ureteroscopic stone extraction.

Aloosh M, Couture F, Fahmy N, Elhilali MM, Andonian S.

Can Urol Assoc J. 2018 Feb;12(2):52-58. doi: 10.5489/cuaj.4570. Epub 2017 Dec 1.

13.

WITHDRAWN: PACE4 Proteolytically Processes LOXL2 with little impact on its catalytic activity.

Okada K, Moon HJ, Finney J, Couture F, Day R, Mure M.

J Biol Chem. 2017 Nov 28. pii: jbc.C117.810978. doi: 10.1074/jbc.C117.810978. [Epub ahead of print]

14.

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L.

Labriet A, De Mattia E, Cecchin E, Lévesque É, Jonker D, Couture F, Buonadonna A, D'Andrea M, Villeneuve L, Toffoli G, Guillemette C.

Front Pharmacol. 2017 Oct 10;8:712. doi: 10.3389/fphar.2017.00712. eCollection 2017.

15.

PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.

Couture F, Sabbagh R, Kwiatkowska A, Desjardins R, Guay SP, Bouchard L, Day R.

Cancer Res. 2017 Dec 15;77(24):6863-6879. doi: 10.1158/0008-5472.CAN-17-1397. Epub 2017 Oct 9.

16.

EJCB - Molecular basis of protein fates in the secretory and endocytic pathways, and beyond.

Couture F, Jansen AM, Taghert P, Brix K.

Eur J Cell Biol. 2017 Aug;96(5):369-371. doi: 10.1016/j.ejcb.2017.06.006. Epub 2017 Jun 15. No abstract available.

PMID:
28754257
17.

Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations.

Łepek T, Kwiatkowska A, Couture F, Ly K, Desjardins R, Dory Y, Prahl A, Day R.

Eur J Cell Biol. 2017 Aug;96(5):476-485. doi: 10.1016/j.ejcb.2017.04.001. Epub 2017 Apr 23.

PMID:
28483279
18.

PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.

Panet F, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Day R.

Eur J Cell Biol. 2017 Aug;96(5):469-475. doi: 10.1016/j.ejcb.2017.03.006. Epub 2017 Mar 21.

PMID:
28347547
19.

Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4.

Małuch I, Levesque C, Kwiatkowska A, Couture F, Ly K, Desjardins R, Neugebauer WA, Prahl A, Day R.

J Med Chem. 2017 Apr 13;60(7):2732-2744. doi: 10.1021/acs.jmedchem.6b01499. Epub 2017 Mar 24.

PMID:
28287731
20.

Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.

Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, Letourneau R, Liu H, Romano A.

Adv Ther. 2017 Jan;34(1):277-279. doi: 10.1007/s12325-016-0442-2. No abstract available.

21.

nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.

Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, Letourneau R, Liu H, Romano A.

Adv Ther. 2016 May;33(5):747-59. doi: 10.1007/s12325-016-0327-4. Epub 2016 Apr 16. Erratum in: Adv Ther. 2016 Nov 24;:.

22.

Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors.

Kwiatkowska A, Couture F, Levesque C, Ly K, Beauchemin S, Desjardins R, Neugebauer W, Dory YL, Day R.

ChemMedChem. 2016 Feb 4;11(3):289-301. doi: 10.1002/cmdc.201500532. Epub 2016 Jan 11.

PMID:
26751825
23.

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.

Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Canadian Blood and Marrow Transplant Group.

Lancet Oncol. 2016 Feb;17(2):164-173. doi: 10.1016/S1470-2045(15)00462-3. Epub 2015 Dec 24. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
26723083
24.

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.

Chen S, Villeneuve L, Jonker D, Couture F, Laverdière I, Cecchin E, Innocenti F, Toffoli G, Lévesque E, Guillemette C.

Pharmacogenet Genomics. 2015 Dec;25(12):573-83. doi: 10.1097/FPC.0000000000000168.

PMID:
26352872
25.

Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.

Couture F, Ly K, Levesque C, Kwiatkowska A, Ait-Mohand S, Desjardins R, Guérin B, Day R.

Biomed Res Int. 2015;2015:824014. doi: 10.1155/2015/824014. Epub 2015 May 31.

26.

Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas.

Iliuta IA, Beauregard JM, Couture F, Douville P, Mac-Way F.

Clin Nucl Med. 2015 Sep;40(9):e448-50. doi: 10.1097/RLU.0000000000000862.

PMID:
26053724
27.

A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.

Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E, Villeneuve L, Harvey M, Court MH, Innocenti F, Toffoli G, Lévesque E, Guillemette C.

Pharmacogenomics J. 2015 Dec;15(6):513-20. doi: 10.1038/tpj.2015.12. Epub 2015 Mar 17.

28.

PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.

Levesque C, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Neugebauer WA, Day R.

Oncotarget. 2015 Feb 28;6(6):3680-93.

29.

Therapeutic uses of furin and its inhibitors: a patent review.

Couture F, Kwiatkowska A, Dory YL, Day R.

Expert Opin Ther Pat. 2015 Apr;25(4):379-96. doi: 10.1517/13543776.2014.1000303. Epub 2015 Jan 7. Review.

PMID:
25563687
30.

Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.

Laverdière I, Guillemette C, Tamouza R, Loiseau P, Peffault de Latour R, Robin M, Couture F, Filion A, Lalancette M, Tourancheau A, Charron D, Socié G, Lévesque É.

Haematologica. 2015 Feb;100(2):275-83. doi: 10.3324/haematol.2014.109884. Epub 2014 Nov 25.

31.

A homozygous loss-of-function variant in MYH11 in a case with megacystis-microcolon-intestinal hypoperistalsis syndrome.

Gauthier J, Ouled Amar Bencheikh B, Hamdan FF, Harrison SM, Baker LA, Couture F, Thiffault I, Ouazzani R, Samuels ME, Mitchell GA, Rouleau GA, Michaud JL, Soucy JF.

Eur J Hum Genet. 2015 Sep;23(9):1266-8. doi: 10.1038/ejhg.2014.256. Epub 2014 Nov 19.

32.

PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.

Couture F, Levesque C, Dumulon-Perreault V, Ait-Mohand S, D'Anjou F, Day R, Guérin B.

Neoplasia. 2014 Aug;16(8):634-43. doi: 10.1016/j.neo.2014.07.010.

33.

Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.

Villa D, George A, Seymour JF, Toze CL, Crump M, Lee C, Buckstein R, Stewart DA, MacDonald D, Foley R, Xenocostas A, Sabloff M, Chua N, Couture F, Larouche JF, Cohen S, Savage KJ, Connors JM, Panzarella T, Carney DA, Dickinson M, Kuruvilla J.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1813-8. doi: 10.1016/j.bbmt.2014.07.015. Epub 2014 Jul 18.

34.

Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations.

Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N; Comité de l'évolution des pratiques en oncologie.

HPB (Oxford). 2015 Jan;17(1):52-65. doi: 10.1111/hpb.12273. Epub 2014 Jun 24. Review.

35.

Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target.

Longuespée R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, Gagnon S, Vergara D, Maffia M, Fournier I, Salzet M, Day R.

Transl Oncol. 2014 May 9. pii: S1936-5233(14)00043-6. doi: 10.1016/j.tranon.2014.04.008. [Epub ahead of print]

36.

Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin.

Gagnon H, Beauchemin S, Kwiatkowska A, Couture F, D'Anjou F, Levesque C, Dufour F, Desbiens AR, Vaillancourt R, Bernard S, Desjardins R, Malouin F, Dory YL, Day R.

J Med Chem. 2014 Jan 9;57(1):29-41. doi: 10.1021/jm400633d. Epub 2013 Dec 23.

PMID:
24359257
37.

Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor.

Kwiatkowska A, Couture F, Levesque C, Ly K, Desjardins R, Beauchemin S, Prahl A, Lammek B, Neugebauer W, Dory YL, Day R.

J Med Chem. 2014 Jan 9;57(1):98-109. doi: 10.1021/jm401457n. Epub 2013 Dec 18.

PMID:
24350995
38.

Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells.

D'Anjou F, Couture F, Desjardins R, Day R.

Methods Mol Biol. 2014;1103:67-82. doi: 10.1007/978-1-62703-730-3_6.

PMID:
24318887
39.

Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO).

Morneau M, Foster W, Lalancette M, Van Nguyen-Huynh T, Renaud MC, Samouëlian V, Letarte N; Comité de l'évolution des pratiques en oncologie; Comité de l'évolution des pratiques en oncologie, Almanric K, Boily G, Bouchard P, Boulanger J, Cournoyer G, Couture F, Gervais N, Goulet S, Guay MP, Kavanagh M, Lemieux J, Lespérance B, Letarte N, Morneau M, Ouellet JF, Pineau G, Rajan R, Roy I, Samson B, Sidéris L, Vincent F.

Gynecol Oncol. 2013 Oct;131(1):231-40. doi: 10.1016/j.ygyno.2013.07.084. Epub 2013 Jul 19. Review.

PMID:
23872191
40.

[The fast eating syndrome. A clinical study group offers preventive interventions].

Lefebvre B, Trépanier D, Couture F, Duguay J, Pépin-Côté J, Kasprzak L, Boily M, Trottier N, Bouchard N, Sutton S.

Perspect Infirm. 2013 May-Jun;10(3):33-6. French. No abstract available.

PMID:
23705279
41.

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ.

J Clin Oncol. 2013 Jul 1;31(19):2477-84. doi: 10.1200/JCO.2012.46.0543. Epub 2013 May 20.

PMID:
23690424
42.

Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.

Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, MacDonald DA, Buckstein R, Lee C, Alzahrani M, Rubinger M, Foley R, Xenocostas A, Sabloff M, Muccilli A, Chua N, Couture F, Larouche JF, Cohen S, Connors JM, Ambler K, Al-Tourah A, Ramadan KM, Kuruvilla J.

J Clin Oncol. 2013 Mar 20;31(9):1164-71. doi: 10.1200/JCO.2012.44.0693. Epub 2013 Feb 11.

PMID:
23401459
43.

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

Lévesque E, Bélanger AS, Harvey M, Couture F, Jonker D, Innocenti F, Cecchin E, Toffoli G, Guillemette C.

J Pharmacol Exp Ther. 2013 Apr;345(1):95-101. doi: 10.1124/jpet.112.202242. Epub 2013 Feb 5.

44.

Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?

Bormanis J, Quirt I, Chang J, Kouroukis CT, MacDonald D, Melosky B, Verma S, Couture F.

Crit Rev Oncol Hematol. 2013 Aug;87(2):132-9. doi: 10.1016/j.critrevonc.2012.12.010. Epub 2013 Jan 26. Review.

PMID:
23357249
45.

Role of proprotein convertases in prostate cancer progression.

Couture F, D'Anjou F, Desjardins R, Boudreau F, Day R.

Neoplasia. 2012 Nov;14(11):1032-42.

46.

The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.

Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R.

J Med Chem. 2012 Dec 13;55(23):10501-11. doi: 10.1021/jm3011178. Epub 2012 Nov 14.

47.
48.

A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for monitoring drug exposure in hematopoietic stem cell transplant recipients.

Laverdière I, Caron P, Couture F, Lévesque E, Guillemette C.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Feb 15;885-886:131-7. doi: 10.1016/j.jchromb.2011.12.029. Epub 2012 Jan 9.

PMID:
22265668
49.

Liquid chromatography-coupled tandem mass spectrometry based assay to evaluate inosine-5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells from stem cell transplant recipients.

Laverdière I, Caron P, Couture F, Guillemette C, Lévesque E.

Anal Chem. 2012 Jan 3;84(1):216-23. doi: 10.1021/ac202404y. Epub 2011 Dec 2.

PMID:
22092180
50.

Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group.

Kuruvilla J, Pintilie M, Stewart D, Lachance S, Power M, Couture F, Xenocostas A, Voralia M, Couban S, Foley R.

Bone Marrow Transplant. 2010 Jul;45(7):1253-5. doi: 10.1038/bmt.2009.321. Epub 2009 Nov 16. No abstract available.

PMID:
19915625

Supplemental Content

Loading ...
Support Center